Clinical Trial

Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Description

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Relacorilant, 100mg QD

Relacorilant is supplied as capsules for oral dosing

Drug - Nab-paclitaxel, 80mg/m^2

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle

Drug - Nab-paclitaxel, 100mg/m^2

Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle

Drug - Relacorilant, 150mg QD

Relacorilant is supplied as capsules for oral dosing

Additional Information

Official Study Title

A Phase 2, Randomized, Open-Label, 3-arm Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Clinical Trial ID

NCT03776812

ParticipAid ID

ejROWe